4shared 920-130 brain dumps VCE record | | Inicio RADIONAVES

Our Training bundle contains PDF Questions and Answers with Exam Simulator View our practice test - braindumps on website - - Inicio RADIONAVES

Pass4sure 920-130 dumps | Killexams.com 920-130 existent questions | http://www.radionaves.com/

920-130 Symposium Express muster Center

Study usher Prepared by Killexams.com Nortel Dumps Experts


Killexams.com 920-130 Dumps and existent Questions

100% existent Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers



920-130 exam Dumps Source : Symposium Express muster Center

Test Code : 920-130
Test designation : Symposium Express muster Center
Vendor designation : Nortel
: 57 existent Questions

where must I sign in for 920-130 exam?
I commenced virtually considering 920-130 exam simply when you explored me approximately it, and now, having chosen it, I sense that I beget settled at the proper preference. I handed examination with exclusive opinions utilising killexams.Com Dumps of 920-130 examination and got 89% marks which is very righteous for me. In the wake of passing 920-130 exam, I beget numerous openings for work now. Much liked killexams.Com Dumps for assisting me evolution my vocation. You shaked the beer!


Got no problem! 3 days preparation of 920-130 actual test questions is required.
It is not the primary time i am using killexamsfor my 920-130 exam, i beget attempted their materials for some vendors examinations, and havent failed as soon as. I absolutely trust on this steering. This time, I additionally had some technical problems with my pc, so I had to touch their customer support to double test some thing. Theyve been top notch and beget helped me kindhearted matters out, in spite of the fact that the problem become on my prevent, not their software program program.


can you correspond with that every one 920-130 questions I had beget been requested in existent check.
hi! im julia from spain. exigency to bypass the 920-130 exam. however. My English may live very bad. The language is facile and lines are quick . No concern in mugging. It helped me wrap up the guidance in 3 weeks and i surpassed wilh 88% marks. now not capable of crack the books. lengthy strains and difficult words compose me sleepy. needed an antiseptic manual badly and finally observed one with the killexams.com mind dumps. I were given totality query and respond . first rate, killexams! You made my day.


Dumps today's 920-130 exam are to live had now.
I will suggest you to arrive perquisite here to remove totality fears related to 920-130 certification due to the fact this is a wonderful platform to proffer you with confident goods for your preparations. I became involved for 920-130 examination but totality way to killexams.Com who supplied me with tremendous products for my coaching. I become actually involved approximately my success however it changed into best 920-130 exam engine that increased my achievement self belief and now I am emotion satisfaction in this unconditional assist. Hats off to you and your incredible services for totality college students and professionals!


Did you attempted this exceptional source of latest dumps.
Hi Team, I beget completed 920-130 in first attempt and thanks a lot for your useful question bank.


actual pick a gape at questions of 920-130 exam are to live had now.
in case you exigency proper 920-130 schooling on how it works and what are the assessments and totality then dont waste it tedious and opt for killexams.com as its miles an closing supply of assist. I additionally wanted 920-130 education and i even opted for this super check engine and were given myself the first-class education ever. It guided me with each thing of 920-130 examand provided the pleasant questions and solutions i beget ever visible. The pick a gape at courses additionally were of very much help.


Do no longer waste some time on looking, simply derive the ones 920-130 Questions from existent test.
i beget advised about your gadgets to numerous partners and companions, and theyre totality extraordinarily fulfilled. a considerable deal obliged killexams.com Questions & solutions for boosting up my career and helping me device nicely for my excessiveexams. a whole lot preferred over again. I exigency to negate that i am your greatest fan! I want you to recognize that I cleared my 920-130 exam these days, deliberating the 920-130 route notes i purchased from you. I solved 86/95 questions within theexam. you are the attribute training company.


proper here is proper supply brand newmodern dumps, correct solutions.
I had taken the 920-130 instruction from the killexams.Com as that modified into a nice platform for the training and that had ultimately given me the fine degree of the steerage to derive the splendid scores inside the 920-130 pick a glance atchecks. I simply loved the manner I got the topics completed within the thoughtprovoking manner and through the abet of the identical; I had in the long speed had been given the detail on the line. It had made my guidance a righteous buy less complex and with the abet of the killexams.Com I were capable of develop well within the existence.


I sense very assured with 920-130 exam bank.
that is an without a doubt valid and dependable resource, with actual 920-130 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest fancy I had with Killexams. I exceeded with a virtually exorbitant score, so Im telling this primarily based on my private experience.


Very tough 920-130 examination questions asked within the examination.
killexams.Com is the most nice way i beget ever lengthy beyond over to derive geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must nigh it down. The element is, it provides for the same problem what I should understand for an examination. Whats more I carry weight various IT assessments, 920-130 with 88% marks. My companion utilized killexams.Com for lots special certificates, totality terrific and big. In reality stable, my individual top alternatives.


Nortel Nortel Symposium Express Call

VoIP certification tracks - Nortel's support certifications | killexams.com existent Questions and Pass4sure dumps

As outlined in a previous tip, agencies are enforcing IP telephony greater commonly on their information infrastructures. The increased deployment has created a necessity for certified IP telephony engineers to provide proven, most reliable-of-breed expertise.

The IP telephony certifications Nortel presently offers are divided into 4 categories: abet expert, Design specialist, aid professional, and Design expert. This tip discusses the Nortel support music.

support professional

The abet expert certifications are intended to display an individual's faculty to implement, function, and troubleshoot a Nortel Networks IP Telephony solution. The assist professional certification displays a candidate with three to six months of suffer that can tackle pursuits technical concerns of a typical Nortel IP Telephony solution.

NNCSS - VoIP Succession BCM three.0

This certification exams the faculty to enforce, function, and troubleshoot the enterprise Communications supervisor three.0. This certification covers hardware, delivery-up, records and voice networking, functions, and troubleshooting the BCM. To pass the certification, two exams beget to live successfully accomplished: expertise specifications and Protocols for IP Telephony options, and Succession BCM three.0. The know-how necessities and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification tests the skill to enforce, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and safety of a single web page CallPilot equipment. To current the certification, two checks must live efficaciously completed: Meridian Database and CallPilot 2.0.

NNCSS - Symposium muster middle Server or Symposium muster middle Server setting up and upkeep

These two certifications test the means to enforce, operate, and troubleshoot the Symposium muster core Server. both certifications cover hardware, application setting up, administration, and upkeep of Symposium designation middle Server four.2, Symposium web client 4.0, and Symposium express three.0. despite the fact, the Symposium muster headquarters Server certification besides checks the structure, customized configuration and integration of the server. To circulate both of these certifications, one exam should live successfully completed: Symposium muster middle or Symposium designation middle installing and upkeep, respectively.

NNCSS - Symposium muster headquarters TAPI/Agent or designation headquarters TAPI/Agent installing and protection

These two certifications gape at various the faculty to enforce, operate, and troubleshoot the Symposium designation core TAPI/Agent. each certifications cowl hardware, utility setting up, administration, and protection of Symposium TAPI 2.three and Symposium Agent 2.three. despite the fact, the Symposium muster middle TAPI/Agent certification besides exams the architecture, integration, and customized configuration of the TAPI/Agent. To hotfoot either of these certifications, one exam exigency to live efficaciously achieved: Symposium designation middle TAPI/Agent or Symposium designation middle TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium express designation headquarters or Symposium express muster headquarters installing and protection

These certifications examine the capability to Place in force, function, and troubleshoot the Symposium express designation middle. both certifications cover hardware, application installation, administration, and maintenance of Symposium categorical muster middle four.2. despite the fact, the Symposium express muster middle certification besides exams the structure and integration of the designation middle. To circulate either of the certifications, one examination exigency to live successfully accomplished: Symposium specific muster middle or Symposium express designation middle Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the potential to enforce, function, and troubleshoot the VoIP Multimedia communique Server (MCS) 5100 2.0. This certification covers setting up of the hardware and software, configuration, maintenance, and administration of the Multimedia verbal exchange Server (MCS) 5100 2.0. To pass the certification, two exams should live correctly completed: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia communication Server (MCS) 5100 2.0. The technology requisites and Protocols for IP Telephony options examination is an overview of convergence applied sciences.

NNCSS - VoIP Succession a thousand/1000M Rls. 3.0 DB Administrator

This certification checks the means to preserve and troubleshoot the VoIP Succession a thousand/1000M Rls. 3.0 DB Administrator. This certification covers the structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the usage of fundamental Alternate Route selection (BARS) and network Alternate Route altenative (NARS). To pass the certification, two tests exigency to live efficaciously achieved: technology requisites and Protocols for IP Telephony options, and Succession 1000/1000M Rls. three.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. 3.0 setting up and renovation

This certification assessments the capability to install, configure, and maintain the VoIP Succession one thousand/1000M Rls. three.0. This certification covers the setting up, architecture, configuration, preservation, and management of the Meridian 1, Succession one thousand Rls. three.0, and Succession 1000M Rls. three.0, web Telephones i2xxx, and Optivity Telephony supervisor (OTM) 2.1. To current the certification, three exams must live efficaciously accomplished: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. three.0 for Technicians, and Succession a thousand/1000M Rls. three.0.

help expert

The aid expert certifications build on the specialist's potential with the aid of demonstrating their skill to Place into effect, operate, and troubleshoot an superior Nortel Networks IP Telephony solution. The assist knowledgeable certifications replicate a candidate with six to 12 months of arms-on event with the potential to lead or support intermediate-level personnel to maintain complicated Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging solutions

This certification checks the faculty to enforce, function, troubleshoot and optimize the VoIP CallPilot Unified Messaging respond 2.0. This certification covers the installation, administration, interoperability, safety, upgrade methods and beget usage for a multi web page CallPilot device. To current the certification, the candidate exigency to first attain their NNCSS - CallPilot Rls. 2.0. because of this, the CallPilot 2.0 Unified Messaging solutions exigency to live efficaciously accomplished to obtain this certification.

NNCSE - Contact center

This certification exams the capacity to implement, operate, troubleshoot and optimize the Contact core products. This certification covers the candidate's capabilities on the Symposium muster headquarters Server (SCCS)/Symposium express muster middle/Symposium internet client, Symposium TAPI carrier provider (TAPI SP), Symposium Agent, and the Symposium internet headquarters Portal. To current the certification, the candidate should first achieve their NNCSS - Symposium muster headquarters Server and the NNCSS - Symposium muster middle TAPI/Agent certification. because of this, the Contact middle examination should live effectively completed to gain this certification.

NNCSE - IP Convergence Succession one thousand/1000M Rls. 3.0

This certification assessments the faculty to deploy, configure, hold, and optimize the VoIP Succession one thousand/1000M Rls. three.0. This certification covers the configuration, succession department workplace (BO), far flung workplace, operation, and Meridian 1 to Succession 1000M three.0 migration processes for the Succession 1000/1000M Rls. three.0, internet Telephones i2xxx, far off office 91xx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, the candidate exigency to first attain their NNCSS - VoIP Succession CSE one thousand Rls. 2.0 or the VoIP Succession a thousand/1000M Rls. 3.0 installation & upkeep certification. because of this, an extra extra intricate edition of the Succession 1000/1000M Rls. 3.0 exam must live efficaciously achieved to gather this certification.

in the IT trade, certifications are a way to validate an individual's skills within a unique area. The above Nortel IP Telephony certifications are one of the most tools that may demonstrate the capabilities of an IP Telephony usher knowledgeable. These certifications couldn't supplant years of commerce experience, but they finish provide the basis to abet and maneuver Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification song.

Richard Parsons (CCIE#5719) is a manager of professional functions for Callisma Inc., a totally owned subsidiary of SBC. He has developed an excellent groundwork in networking ideas, advanced troubleshooting, and monitoring in areas such as optical, ATM, VoIP, routed, routing, and storage infrastructures. wealthy resides in Atlanta GA, and is a graduate of Clemson tuition. His historical past contains senior and fundamental consulting positions at overseas network functions, Lucent, and Callisma.


Nortel: Wall road Analysts unhappy With this autumn effects | killexams.com existent Questions and Pass4sure dumps

No result found, are trying fresh keyword!After the convention muster the day gone by, americaSecurities sharply dropped its 2007/2008 revenue and EPS estimates in addition to its inventory target rate. americanow expects Nortel to beget salary of $eleven.forty nine-billion ...

Symon Communications joins Nortel choose Product program in EMEA | killexams.com existent Questions and Pass4sure dumps

LONDON--(business WIRE)--June 14, 2005--Symon Communications Ltd, a leading global company of actual-time communications solutions for the designation centre business, has been chosen with the aid of Nortel (NYSE:NT)(TSX:NT) to live a fragment of its select Product software (SPP) in Europe, the headquarters East and Africa (EMEA).

The programme is the precise tier of Nortel's Developer software, which provides participants with the haphazard to enlarge and bring leading-side customer solutions. Symon's selection changed into based on Nortel's analysis of Symon's marketing strategy in addition to consumer enter.

"This announcement is awfully vital for Symon and Nortel customers alike," talked about Nelson Smelker, UK managing director, Symon Communications. "The undeniable fact that Symon and their true-time products are being particularly informed by means of Nortel illustrates the self belief that the resellers and their customers beget in their products. Nortel is one in every of their closest partners and they trust that their inclusion on the select Product application in Europe demonstrates that they are a legitimate and committed partner, in for the long haul."

"we are at totality times seeking to simplify the way they work with their channel companions as a way to give altenative and lawful considerable overall options to their halt consumers," preeminent Paul Templeton, vp, commercial enterprise options, EMEA, Nortel. "we are very excited to beget Symon Communications live fragment of the EMEA select Product software, a strategic initiative certainly designed to supply their valued clientele access to suggested third-celebration products by means of Nortel channel partners."

The opt for Product application makes it feasible for shrunk Nortel Resellers (CNRs) to order preempt third-celebration products below particular terms and stipulations of sale that strategically complement the Nortel product portfolio and create expansive value for its valued clientele. choose items are defined as Nortel's most extremely counseled third-birthday celebration items for a specific performance. products in Symon's award-profitable actual-time communications portfolio, which includes Symon commercial enterprise Server (SES), Symon Vista and Symon TargetVision, beget totality been chosen as choose items by way of Nortel.

in addition, Symon's latest group of workers management solution, Symon group, has been given an Orderable compatible designation, allowing the respond to live ordered direct by the exercise of Nortel ordering techniques.

Symon has been a a hit registered member of Nortel's EMEA Developer program seeing that July 2004. Nortel's Developer program has labored with creative businesses that complement and lengthen its product portfolio for over twenty years. The Developer application formalizes these ally relationships, featuring an exceptional partnering framework that promotes options with complete compatibility between add-ons.

The Nortel Developer application has diverse levels of membership, starting from the entry degree, basis tier, Open Developer, where builders profit entry to a number of apparatus to facilitate their evolution efforts, through to Developer associate stage, where Nortel actively markets the Developer accomplice items. one of the vital pre-requisites for Developer associate status is the successful completion of compatibility testing, which raises consumer self assurance in the built-in solution. ultimately, builders might besides graduate by way of invitation best to the choose Product program stage, which is the desirable tier of the Developer program. Nortel choose products are strategic pile blocks for Nortel creative structure and assist in featuring purchasers with essentially the most advantageous and efficient respond for their conversation needs. For more information on totality Nortel choose items, tickle talk over with www.nortel.com/select. For additional counsel on the Developer application, tickle talk over with www.nortel.com/prd/dpp.

About Symon Communications

Symon Communications Ltd, primarily based in Beckenham, UK, produces pleasant utility and hardware solutions to collect, analyse, document and song real-time, mission-critical productiveness suggestions for contact centres and different commerce functions. This information contains company metrics, group of workers effectivity and operations indicators.

Symon Communications' award-profitable items encompass browser-based Symon neighborhood personnel management utility and Symon Vista statistics presentation tools, Symon TargetVision visual messaging methods, patented Symon NetLite II wallboards, Symon DeskView visual computer messaging and alerting utility and the Symon commerce Server statistics administration device.

installed in more than 6,000 centres global, greater than four million clients view Symon Communications' products day by day. clients consist of Kwik fit, American categorical, Eli Lilly, Deutsche Telekom and Royal Mail group.

Symon Communications Ltd. is a unconditionally owned subsidiary of Symon Communications Inc. based mostly out of Plano, Texas.

About Nortel

Nortel is a identified leader in supplying communications capabilities that boost the human adventure, ignite and power world commerce, and cozy and protect the area's most valuable tips. Serving both carrier company and commercial enterprise customers, Nortel supplies resourceful expertise options encompassing conclusion-to-conclusion broadband, Voice over IP, multimedia services and functions, and wireless broadband designed to support individuals solve the realm's premier challenges. Nortel does company in additional than a hundred and fifty nations. For more information, talk over with Nortel on the web at www.nortel.com. For the latest Nortel news, quest counsel from www.nortel.com/information.

definite assistance covered during this press release is ahead-searching and is field to essential risks and uncertainties. The consequences or events anticipated in these statements may additionally fluctuate materially from actual effects or pursuits. components which might occasions outcomes or events to vary from existing expectations encompass, amongst different things: the outcomes of regulatory and criminal investigations and civil litigation actions related to Nortel's restatements and the impact any resulting legal judgments, settlements, penalties and costs could beget on Nortel's effects of operations, pecuniary condition and liquidity, and any linked competencies dilution of Nortel's typical shares; the findings of Nortel's independent evaluate and implementation of advised remedial measures; the influence of the unbiased overview with recognize to revenues for specific recognized transactions, which evaluate could beget a particular emphasis on the underlying conduct that ended in the introductory focus of those revenues; the restatement or revisions of Nortel's previously announced or filed economic consequences and ensuing execrable publicity; the actuality of fabric weaknesses in Nortel's internal manage over fiscal reporting and the conclusion of Nortel's administration and impartial auditor that Nortel's interior maneuver over monetary reporting is ineffective, which could continue to affect Nortel's potential to document its effects of operations and monetary situation precisely and in a well timed manner; the beget an result on of Nortel's and NNL's failure to well timed file their economic statements and linked fitful reviews, including Nortel's want of faculty to access its shelf registration observation filed with the us Securities and alternate commission (SEC); ongoing SEC experiences, which may halt up in adjustments to Nortel's and NNL's public filings; the affect of management changes, together with the termination for understanding behind Nortel's former CEO, CFO and Controller in April 2004; the sufficiency of Nortel's restructuring activities, together with the work device introduced on August 19, 2004 as up-to-date on September 30, 2004 and December 14, 2004, together with the odds for better specific charges to live incurred in reference to restructuring moves compared to the estimated charges of such actions; cautious or reduced spending via Nortel's valued clientele; elevated consolidation among Nortel's customers and the want of purchasers in obvious markets; fluctuations in Nortel's working outcomes and typical business, economic and market conditions and boom fees; fluctuations in Nortel's money flow, stage of staggering debt and current debt rankings; Nortel's monitoring of the capital markets for opportunities to enlarge its capital structure and monetary flexibility; Nortel's capability to recruit and maintain certified personnel; using cash collateral to abet Nortel's ordinary path enterprise actions; the dependence on Nortel's subsidiaries for funding; the affect of Nortel's described profit plans and deferred tax assets on effects of operations and Nortel's cash circulate; the antagonistic resolution of classification actions, litigation within the usual path of enterprise, highbrow property disputes and similar concerns; Nortel's dependence on fresh product pile and its faculty to prophesy market demand for specific items; Nortel's capacity to integrate the operations and applied sciences of bought corporations in an efficacious method; the influence of swift technological and market exchange; the affect of price and product competitors; boundaries to exotic enlarge and world economic conditions, notably in emerging markets and including hobby expense and currency trade fee fluctuations; the influence of clarification and consolidation in the telecommunications business; alterations in law of the information superhighway; the impact of the credit dangers of Nortel's customers and the impact of client financing and commitments; inventory market volatility generally and because of acceleration of the constrict date of Nortel's forward buy contracts; execrable tendencies associated with Nortel's supply contracts and constrict manufacturing agreements, including because of using a sole supplier for a key fragment of obvious optical networks solutions; the beget an impact on of Nortel's supply and outsourcing contracts that comprise nascence and installing provisions, which, if no longer met, might outcome in the payment of gargantuan penalties or liquidated damages; and the longer term success of Nortel's strategic alliances. For additional information with recognize to unavoidable of these and different elements, descry probably the most concomitant Annual file on form 10-okay and Quarterly document on form 10-Q filed through Nortel with the SEC. unless otherwise required through pertinent securities laws, Nortel disclaims any purpose or responsibility to update or revise any forward-searching statements, whether on account of fresh tips, future events or otherwise.

Nortel, the Nortel brand and the Globemark are trademarks of Nortel Networks. Symon, Symon enterprise Server, Symon NetLite II, Symon group, Symon TargetVision and Symon Vista are emblems of Symon Communications, Inc.

Use of the terms "partner" and "partnership" doesn't suggest a criminal partnership between Nortel and every other birthday party.


920-130 Symposium Express muster Center

Study usher Prepared by Killexams.com Nortel Dumps Experts


Killexams.com 920-130 Dumps and existent Questions

100% existent Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers



920-130 exam Dumps Source : Symposium Express muster Center

Test Code : 920-130
Test designation : Symposium Express muster Center
Vendor designation : Nortel
: 57 existent Questions

where must I sign in for 920-130 exam?
I commenced virtually considering 920-130 exam simply when you explored me approximately it, and now, having chosen it, I sense that I beget settled at the proper preference. I handed examination with exclusive opinions utilising killexams.Com Dumps of 920-130 examination and got 89% marks which is very righteous for me. In the wake of passing 920-130 exam, I beget numerous openings for work now. Much liked killexams.Com Dumps for assisting me evolution my vocation. You shaked the beer!


Got no problem! 3 days preparation of 920-130 actual test questions is required.
It is not the primary time i am using killexamsfor my 920-130 exam, i beget attempted their materials for some vendors examinations, and havent failed as soon as. I absolutely trust on this steering. This time, I additionally had some technical problems with my pc, so I had to touch their customer support to double test some thing. Theyve been top notch and beget helped me kindhearted matters out, in spite of the fact that the problem become on my prevent, not their software program program.


can you correspond with that every one 920-130 questions I had beget been requested in existent check.
hi! im julia from spain. exigency to bypass the 920-130 exam. however. My English may live very bad. The language is facile and lines are quick . No concern in mugging. It helped me wrap up the guidance in 3 weeks and i surpassed wilh 88% marks. now not capable of crack the books. lengthy strains and difficult words compose me sleepy. needed an antiseptic manual badly and finally observed one with the killexams.com mind dumps. I were given totality query and respond . first rate, killexams! You made my day.


Dumps today's 920-130 exam are to live had now.
I will suggest you to arrive perquisite here to remove totality fears related to 920-130 certification due to the fact this is a wonderful platform to proffer you with confident goods for your preparations. I became involved for 920-130 examination but totality way to killexams.Com who supplied me with tremendous products for my coaching. I become actually involved approximately my success however it changed into best 920-130 exam engine that increased my achievement self belief and now I am emotion satisfaction in this unconditional assist. Hats off to you and your incredible services for totality college students and professionals!


Did you attempted this exceptional source of latest dumps.
Hi Team, I beget completed 920-130 in first attempt and thanks a lot for your useful question bank.


actual pick a gape at questions of 920-130 exam are to live had now.
in case you exigency proper 920-130 schooling on how it works and what are the assessments and totality then dont waste it tedious and opt for killexams.com as its miles an closing supply of assist. I additionally wanted 920-130 education and i even opted for this super check engine and were given myself the first-class education ever. It guided me with each thing of 920-130 examand provided the pleasant questions and solutions i beget ever visible. The pick a gape at courses additionally were of very much help.


Do no longer waste some time on looking, simply derive the ones 920-130 Questions from existent test.
i beget advised about your gadgets to numerous partners and companions, and theyre totality extraordinarily fulfilled. a considerable deal obliged killexams.com Questions & solutions for boosting up my career and helping me device nicely for my excessiveexams. a whole lot preferred over again. I exigency to negate that i am your greatest fan! I want you to recognize that I cleared my 920-130 exam these days, deliberating the 920-130 route notes i purchased from you. I solved 86/95 questions within theexam. you are the attribute training company.


proper here is proper supply brand newmodern dumps, correct solutions.
I had taken the 920-130 instruction from the killexams.Com as that modified into a nice platform for the training and that had ultimately given me the fine degree of the steerage to derive the splendid scores inside the 920-130 pick a glance atchecks. I simply loved the manner I got the topics completed within the thoughtprovoking manner and through the abet of the identical; I had in the long speed had been given the detail on the line. It had made my guidance a righteous buy less complex and with the abet of the killexams.Com I were capable of develop well within the existence.


I sense very assured with 920-130 exam bank.
that is an without a doubt valid and dependable resource, with actual 920-130 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest fancy I had with Killexams. I exceeded with a virtually exorbitant score, so Im telling this primarily based on my private experience.


Very tough 920-130 examination questions asked within the examination.
killexams.Com is the most nice way i beget ever lengthy beyond over to derive geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must nigh it down. The element is, it provides for the same problem what I should understand for an examination. Whats more I carry weight various IT assessments, 920-130 with 88% marks. My companion utilized killexams.Com for lots special certificates, totality terrific and big. In reality stable, my individual top alternatives.


Unquestionably it is hard assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals derive sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers arrive to us for the brain dumps and pass their exams joyfully and effortlessly. They never trade off on their review, reputation and attribute on the grounds that killexams review, killexams reputation and killexams customer certainty is imperative to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report objection, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off haphazard that you descry any inaccurate report posted by their rivals with the designation killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protest or something fancy this, simply recall there are constantly dreadful individuals harming reputation of righteous administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

Back to Braindumps Menu


000-278 questions answers | 000-853 rehearse test | 000-541 examcollection | 000-975 brain dumps | CIA-II free pdf | COG-480 test prep | 650-312 exam prep | 000-N19 questions and answers | 000-229 pdf download | HP2-B71 existent questions | C90-06A free pdf | S90-01 rehearse test | OCS free pdf download | VCAP5-DCD braindumps | 050-640 test questions | HP0-J40 test prep | CAT-240 VCE | 9L0-007 mock exam | 920-195 braindumps | C2090-424 rehearse questions |


920-130 | 920-130 | 920-130 | 920-130 | 920-130 | 920-130

Slaughter your 920-130 exam at first attempt!
killexams.com Nortel Certification study guides are setup by IT professionals. Lots of students beget been complaining that there are too many questions in so many rehearse exams and study guides, and they are just tired to afford any more. Seeing killexams.com experts work out this comprehensive version while still guarantee that totality the scholarship is covered after deep research and analysis. Everything is to compose convenience for candidates on their road to certification.

killexams.com beget its experts operating continuously for the collection of existent exam questions of 920-130. totality the pass4sure questions and answers of 920-130 accrued by their institution are seemed into and updated by using their 920-130 assured group. They stay related to the applicants showed up inside the 920-130 test to derive their reviews about the 920-130 test, they accumulate 920-130 exam suggestions and traps, their revel in about the tactics applied as a fragment of the existent 920-130 exam, the errors they achieved in the actual exam and later on modify their material as needs be. Click http://killexams.com/pass4sure/exam-detail/920-130 killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for totality tests on website
PROF17 : 10% Discount Coupon for Orders more than $69
DEAL17 : 15% Discount Coupon for Orders greater than $99
OCTSPECIAL : 10% Special Discount Coupon for totality Orders
When you fancy their pass4sure questions and answers, you will sense positive about every one of the subject matters of exam and feel that your perception has been notably moved forward. These pass4sure questions and answers arent simply rehearse questions, those are actual exam questions and answers that are sufficient to pass the 920-130 exam at the first attempt.

killexams.com beget their experts Team to guarantee their Nortel 920-130 exam questions are dependably the most current. They are at the whole extraordinarily close with the exams and testing consciousness.

How killexams.com maintain Nortel 920-130 exams updated?: they beget their uncommon procedures to realize the maximum recent exams statistics on Nortel 920-130. Now after which they touch their accomplices who're especially at ease with the exam simulator recognition or once in a while their customers will email us the latest enter, or they were given the most current update from their dumps carriers. When they determine the Nortel 920-130 exams changed then they updates them ASAP.

On the off prep that you honestly arrive up quick this 920-130 Symposium Express muster headquarters and might choose no longer to sit tight for the updates then they will give you complete refund. however, you should send your score respond to us with the goal that they will beget a exam. They will give you complete refund quick amid their working time when they derive the Nortel 920-130 score document from you.

Nortel 920-130 Symposium Express muster headquarters Product Demo?: they beget both PDF model and Testing Software. You can exam their product web page to perceive what it would appear that like.

At the point when will I derive my 920-130 cloth once I pay?: Generally, After successful payment, your username/password are sent at your e mail cope with within 5 min. It may besides pick Little longer in case your answers postpone in freight authorization.

killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for totality tests on website
PROF17 : 10% Discount Coupon for Orders extra than $69
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
OCTSPECIAL : 10% Special Discount Coupon for totality Orders


920-130 | 920-130 | 920-130 | 920-130 | 920-130 | 920-130


Killexams C2180-529 brain dumps | Killexams ST0-47W rehearse test | Killexams VCP410 existent questions | Killexams ST0-130 rehearse Test | Killexams 000-419 study guide | Killexams 000-139 VCE | Killexams CPHQ braindumps | Killexams TT0-101 exam prep | Killexams PET bootcamp | Killexams 000-138 examcollection | Killexams 1Z0-878 mock exam | Killexams DC0-261 free pdf download | Killexams C9560-652 rehearse test | Killexams EW0-100 dumps | Killexams HP0-760 free pdf | Killexams 00M-225 dump | Killexams 000-M91 rehearse questions | Killexams ITIL-F questions and answers | Killexams CLEP exam prep | Killexams HP2-B129 brain dumps |


Exam Simulator : Pass4sure 920-130 Exam Simulator

View Complete list of Killexams.com Brain dumps


Killexams P2050-006 questions and answers | Killexams 000-191 rehearse test | Killexams MB3-214 study guide | Killexams 500-170 questions and answers | Killexams JN0-330 braindumps | Killexams 920-325 dumps | Killexams 310-053 bootcamp | Killexams 000-007 braindumps | Killexams LOT-803 existent questions | Killexams LOT-404 free pdf | Killexams HP0-M18 rehearse test | Killexams ITILF2011 free pdf | Killexams LOT-986 exam prep | Killexams CPEA questions answers | Killexams 1Z0-864 examcollection | Killexams HPE6-A29 dumps questions | Killexams A6 pdf download | Killexams C4040-129 brain dumps | Killexams 9A0-383 VCE | Killexams 922-093 free pdf |


Symposium Express muster Center

Pass 4 sure 920-130 dumps | Killexams.com 920-130 existent questions | http://www.radionaves.com/

TravelCenters of America LLC Third Quarter 2018 Conference muster Scheduled for Monday, November 5th | killexams.com existent questions and Pass4sure dumps

WESTLAKE, Ohio--(Business Wire)--TravelCenters of America LLC (Nasdaq: TA) today announced that it plans to issue a press release containing its third quarter 2018 pecuniary results before the Nasdaq opens for trading on Monday, November 5, 2018. Later that morning, at 10:00 a.m. Eastern Time, Chief Executive Officer Andy Rebholz, President and Chief Operating Officer Barry Richards and Chief pecuniary Officer and Treasurer Bill Myers will host a conference muster to review the third quarter 2018 results and to pick questions.

The conference muster telephone number is (877) 329-4614. Participants calling from outside the United States and Canada should dial (412) 317-5437. No pass code is necessary to access the muster from either number. Participants should dial in about 15 minutes prior to the scheduled start of the call. A replay of the conference muster will live available through Monday, November 12, 2018. To hear the replay, dial (412) 317-0088. The replay pass code is 10123843.

A live audio webcast of the conference muster will besides live available in a listen-only mode on the company's website, which is located at www.ta-petro.com. Participants who want to access the webcast should visit the company's website about five minutes before the call. The archived webcast will live available for replay on the company's website after the call.

About TravelCenters of America LLC:

TA's nationwide commerce includes travel centers located in 43 U.S. states and in Canada and standalone restaurants in 13 states. TA's travel centers operate under the "TravelCenters of America," "TA," "TA Express," "Petro Stopping Centers" and "Petro" brand names and proffer diesel and gasoline fueling, restaurants, truck repair services, travel/convenience stores and other services designed to provide attractive and efficient travel experiences to professional drivers and other motorists. TA's standalone restaurants operate principally under the "Quaker Steak & Lube" brand name.

TravelCenters of America LLCKatie Strohacker, 617-796-8251Senior Director, Investor Relations


Gilead Sciences Inc (GILD) Q3 2018 Earnings Conference muster Transcript | killexams.com existent questions and Pass4sure dumps

Image source: The Motley Fool.

Gilead Sciences Inc  (NASDAQ: GILD)Q3 2018 Earnings Conference CallOct. 25, 2018, 4:30 p.m. ET

Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2018 Earnings Conference Call. My designation is Cherie, and I will live your conference operator today. At this time, totality participants are in a listen-only mode. And as a reminder, this conference muster is being recorded.

I would now fancy to turn the muster over to Sung Lee, Vice President of Investor Relations. tickle travel ahead.

Thank you, Cherie, and righteous afternoon, everyone. Just after market nigh today, they issued a press release with earnings results for the third quarter 2018. The press release and minute slides are available on the Investor Relations section of the Gilead website.

The speakers on today's muster will live Robin Washington, Executive Vice President and Chief pecuniary Officer; Laura Hamill, Executive Vice President, Worldwide Commercial Operations; John McHutchison, Chief Scientific Officer and Head of Research and Development; and John Milligan, President and Chief Executive Officer.

Before they open with their prepared comments, let me remind you that they will live making forward-looking statements, including plans and expectations with respect to products, product candidates, pecuniary projections and the exercise of capital, totality of which involve unavoidable assumptions, risks and uncertainties that are beyond their control and could occasions actual results to vary materially from these statements. A description of these risks can live establish in their latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any responsibility to update any forward-looking statements made during this call.

Non-GAAP pecuniary measures will live used to abet you understand the company's underlying commerce performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, as well as on the Gilead website.

I will now turn the muster over to Robin.

Thank you, Sung, and righteous afternoon, everyone. They are pleased to share their pecuniary results for the third quarter of 2018. Before I derive into the pecuniary results and commercial highlights for the quarter, I'd fancy to welcome Laura Hamill, who recently joined Gilead as Executive Vice President, Worldwide Commercial Operations. They are cheerful to beget this key position filled, and are excited to beget Laura on their team.

Laura is quickly becoming close with their commerce and has already provided significant commercial expertise on several strategic fronts. You'll hear from Laura in a few minutes, followed by John McHutchison with an update on their R&D efforts and then John Milligan with a few closing comments.

We had very strong execution in the third quarter, during which their HIV franchise achieved record quarterly sales. HCV revenues continued to live more predictable and in-line with their expectations, and further progress was made in cell therapy, including the approval of Yescarta in Europe. Total revenues for the third quarter were $5.6 billion with non-GAAP diluted earnings per share of $1.84. This compares to total revenues of $6.5 billion and non-GAAP diluted earnings per share of $2.27 for the same term final year.

Starting with HIV, product sales for the third quarter were $3.7 billion, up 12% year-over-year and 2% sequentially. The year-over-year enlarge was primarily due to the continued strong uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. With 19% year-over-year revenue growth and 11% year-over-year prescription growth, their US HIV commerce continues to reflect strong underlying demand for Descovy-based regimens, which now account for 74% of Gilead's total US HIV prescription volume.

Sequentially, US HIV sales were up 5%, reflecting strong demand for Biktarvy. Payer mix in the third quarter was similar to the second quarter, where it was approximately equally split between private pay and government segments. In the second complete quarter since its FDA approval in February, Biktarvy generated $375 million in sales in the US, becoming the number one prescribed regimen for both treatment-naive and switch patients. Biktarvy is on track to overtake Genvoya as the most successful launch in HIV history, as measured by the first 12 months of product sales. Approximately 85% of Biktarvy's US prescriptions came from switches. Of these switches, approximately one quarter came from regimens containing dolutegravir.

Truvada for PrEP continued to grow. They appraise that more than 193,000 individuals were taking Truvada for PrEP as they exited the quarter. Early performance indicators for the HIV prevention and Truvada for PrEP television campaigns launched in the second quarter are encouraging. Since the launch of these campaigns, they seen active appointment with campaign-related websites and a nearly 50% enlarge in the number of weekly fresh subscribers compared to the pre-campaign averages earlier in the year.

Turning to Europe, HIV sales were down 11% year-over-year, primarily due to the availability of generics in several markets. The decline was partially offset by the continued uptake of their Descovy-based regimens, which now comprise approximately 70% of their HIV product revenues in Europe. As anticipated, they saw a sequential decline in sales in the third quarter, primarily due to the additional impact of generics in unavoidable countries and the seasonal impact of holiday schedules in various countries. To date, in some countries, the impact from generics has not been as significant as expected.

Since receiving marketing authorization from European Commission in June, Biktarvy has launched in Germany and some of the smaller countries in the EU. In Germany, they are seeing considerable early uptake where Biktarvy is tracking at least as well as Genvoya for the same term after approval. Also, Biktarvy is already among the top five most prescribed regimen for both treatment-naive and switch patients, with about a third of the switches coming from dolutegravir-containing regimens. Genvoya remained the number one prescribed regimen for treatment-naive and switch patients in the EU-5 collectively for the sixth consecutive quarter.

Turning to HIV (ph), product sales for the third quarter were $902 million, down 59% year-over-year and down 10% sequentially. To date, their performance in the HCV market continued to align with their expectations of gradual sequential declines with fewer patients seeking treatment. In September, they announced plans to launch authorized generic versions of Epclusa and Harvoni in the United States in January 2019 through a newly created subsidiary, Asegua Therapeutics LLC.

The list prices of the authorized generics will live comparable to the current net prices of the branded versions. They believe these authorized generics could reduce out of pocket expenses for patients, enlarge pricing transparency, and open up access to their HCV medicines for patients covered by Medicaid. This solution allows us to quickly introduce a lower priced alternative to their HCV medications without significant disruption to the healthcare system or their business.

Turning to their cell therapy franchise. Sales of Yescarta were $75 million for the third quarter, up 10% sequentially. They are pleased with the progress we've made with Yescarta since its approval by the US FDA one year ago. They now beget 64 centers certified to provide treatment for Yescarta. As they continue to descry patient inflows at certified centers, they beget besides observed variability in volume as some centers enthusiastically embraced this novel therapy and others adopt treatment more slowly.

We've turned their focus to working with centers to enhance patient flows. They are besides educating community oncologists about cell therapy and how they can connect their patients to cancer centers for preempt treatment. They hope to descry continued demand as their certified centers gain broader suffer with Yescarta and community oncologists become increasingly aware of this life-saving therapy.

Recently, CMS approved an NTAP, fresh Technology Add-on Payment, to assist the reimbursement of CAR T therapy within the hospital setting while they await the creation of a CAR T specific DRG through CMS. We're very encouraged with the speed in which CMS has recognized the value of Yescarta for cancer patients, who beget speed out of treatment options in relapsed refractory DLBCL. They gape forward to working with CMS to create a dedicated DRG code reflective of the value Yescarta brings to patients.

As I previously mentioned, Yescarta was approved in the EU toward the halt of August. They are working diligently across Europe to certify approximately 20 centers by the halt of 2018. They are pleased with the progress and commercial performance seen to date with Yescarta, which is consistent with their expectations. Going forward, they anticipate a steady and measured launch as reimbursement, referrals and headquarters logistics help to accommodate more patients.

Turning to their cardiovascular products, Letairis and Ranexa generated sales of $241 million and $178 million respectively in the third quarter. While the US patent for ambrisentan, the active agent in Letairis expired in July of this year, they beget not seen any impact to their sales as a result of the loss of exclusivity, because the single shared REMS program necessary to allow generic ambrisentan to launch has not yet been FDA approved. There is no specific PDUFA date associated with this approval and the timeline for FDA action is unknown. As they gape ahead, they anticipate Letairis sales to continue for the residuum of this year. However, sales beyond this timeframe are uncertain.

Now turning to expenses, non-GAAP R&D expenses were $844 million for the third quarter, up 13% compared to the same term final year. Non-GAAP SG&A expenses were $852 million for the third quarter, up 6% compared to the same term final year. The increases in both non-GAAP R&D expenses and SG&A expenses were primarily due to higher costs to support the growth of their commerce following the acquisition of Kite.

Our non-GAAP efficacious tax rate in the third quarter was 19.9% compared to 25.7% in the same term final year, primarily due to reduction of the US corporate tax rate as a result of Tax Reform. On a sequential basis, their non-GAAP efficacious tax rate was higher compared to the second quarter rate of 13.4% due to a benign settlement of a tax examination in the second quarter.

Moving to their balance sheet. As of September 30, 2018, they had $30.8 billion of cash and investments. During the third quarter, they generated $2.2 billion in operating cash flow, repaid $1.8 billion senior notes upon maturity, paid cash dividends of $742 million, and repurchased approximately 6 million shares of stock for $449 million. The year is progressing consistent with their expectations, with the exception of the durability of Letairis revenues and the lower impact of HIV generics. The combined profit from these two exceptions is approximately $400 million. Therefore, they are raising their full-year net product sales guidance.

Net product sales are expected to live in the purview of $20.8 billion to $21.3 billion. Their guidance is subject to a number of uncertainties which are outlined in slide 35 of their earnings muster presentation. For the full-year, their non-GAAP efficacious tax rate is expected to live in the purview of 18% to 20%. totality other components of their guidance remain unchanged.

I will now turn the muster over to Laura.

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

Thank you, Robin, and righteous afternoon. I'm thrilled to live fragment of the Gilead team and appreciate how welcoming everyone has been during my first six weeks as I'm getting to know the faultfinding success factors for their current and future therapies. I've had the opening to learn more about Gilead's portfolio by participating in several therapeutic advisory board meetings, scientific conferences, visiting some of their cancer institutions that are providing treatments with Yescarta, and engaging with many passionate Gilead employees. The commercial and field teams beget a deep commitment to support healthcare providers as they meet the needs of patients around the world. It's a privilege to live joining Gilead at this time with the introduction of Yescarta as well as Biktarvy, which is on track for an outstanding launch. They are continuing to shift treatment paradigms.

I besides want to concede the innovative approach the team has taken in the United States to enlarge access to their hepatitis C treatments. Next year their subsidiary Asegua will launch authorized generic versions of Harvoni and Epclusa, a medication they believe has a unique clinical profile as a pan-genotypic and pan-fibrotic single-tablet regimen. As they prepare for their next set of launches, they will bring their deep expertise in pile fresh markets, as well as capabilities to compete in existing markets with many therapeutic options.

The teams around the world are motivated by Gilead's mission to bring innovative medicine to more than 13 million patients with life-threatening illnesses. I gape forward to sharing their commercial progress with you during their next quarterly update. I will now turn the muster over to John McHutchison.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Thank you, Laura. Welcome and thank you, everybody for joining us today. I'd fancy to start by talking about the progress they are making across their later-stage pipeline. As they enter the final quarter of the year and gape ahead to 2019, they anticipate readouts from five phase 3 studies over the next nine months. The American College of Rheumatology Meeting finished yesterday in Chicago. So I'll open with some commentary about their work in the zone of inflammation, starting with filgotinib, which as you know, is the selective JAK1 inhibitor.

Last month they announced positive results from FINCH 2, the first of three phase 3 studies to readout in patients with rheumatoid arthritis. FINCH 2 compares filgotinib to placebo, each added to conventional disease-modifying anti-rheumatic drugs, or DMARDs in 423 patients who beget previously not had an adequate response to biologic therapy. Filgotinib was generally well tolerated and met the study's primary endpoint in terms of the harmony of patients achieving an ACR20 at week 12.

In addition, key secondary endpoints, including ACR50 and ACR70 responses and the rates of low disease activity and remission were totality higher with filgotinib compared to placebo. Importantly for these endpoints, they besides preeminent a dose dependency as efficacy rates were numerically higher with the 200 milligram once daily dose of filgotinib, compared to the 100 milligram daily dose. The initial readout of the first phase 3 data adds to their excitement about the potential of filgotinib, obviously.

We hope results from two other phase 3 studies of filgotinib, FINCH 1 and FINCH 3, to live available in the first quarter of next year, and it's supported by the data to form the basis of their filings for regulatory approvals globally. As a reminder, FINCH 1 is a 52 week randomized study comparing both doses of filgotInib, plus methotrexate to adalimumab plus methotrexate and to methotrexate alone in patients who beget previously had an inadequate response to methotrexate. FINCH 3 is a 52 week randomized study comparing filgotinib alone to methotrexate alone and to the combination of filgotinib plus methotrexate in methotrexate-naive patients.

Now their faculty to file the NDA for filgotinib is contingent on data from the MANTA study. As you may recall, MANTA is a safety study in men with ulcerative colitis that was requested by the FDA and is designed to address non-clinical findings observed in preclinical animal studies. Because their phase 3 FINCH trials beget enrolled more rapidly than anticipated, enrollment in MANTA will likely live the rate limiting factor to filing an NDA in the United States. While they beget been making every effort to expedite enrollment, the complete impact of the efforts and their impact on the overall timeline are uncertain at this time.

Results from the EQUATOR study, a phase 2 trial of filgotinib in 131 adults with active psoriatic arthritis were presented this week at ACR in a plenary session and concurrently published in The Lancet. The study besides achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at week 16. The study demonstrated an impressive ACR20 response of 80% to filgotinib 200 milligrams daily, versus 33% for placebo. The ACR50 and ACR70 responses were besides significantly higher for filgotinib compared to placebo. Based upon the strength of these data, they are excited to live initiating plans for their phase 3 program and are enthusiastic about what this may carry weight for people animated with psoriatic arthritis and whose disease is not responded to prior treatments.

Last month they announced that filgotinib met its primary efficacy endpoint in the phase 2 TORTUGA study in adults with moderately to severely active ankylosing spondylitis. Patients treated with filgotinib achieved significantly greater improvement in the ankylosing spondylitis disease activity score at week 12 compared to placebo. These results which were besides published in The Lancet this week, compare favorably to those seen with other known DMARDs commonly known to treat ankylosing spondylitis patients. We'll determine the next steps for the program in the coming months.

Finally in the inflammation therapeutic area, I'm pleased to share that a phase 2 study evaluating three investigational therapies, filgotinib; GS-9876, a Syk inhibitor; and tirabrutinib, a BTK inhibitor in patients with active Sjogren syndrome has fully enrolled 140 patients.

Now turning to HIV, they presented 96-week data at IDWeek in San Francisco earlier this month from an ongoing phase 3 study evaluating the safety and efficacy of Biktarvy for the treatment of HIV infection in treatment-naive adults. The data at two years authenticate the efficacy and safety profile of Biktarvy and showed that Biktarvy continued to live well tolerated with no cases of treatment-emergent resistance.

Moving on to liver diseases. The Liver Meeting will live held in San Francisco early next month, where they will present data from more than 50 abstracts across their programs in NASH, primary sclerosing cholangitis, hepatitis B and hepatitis C. In NASH, they are advancing multiple investigational compounds for the treatment of advanced fibrosis, that is patients with Stage 3 and Stage 4 fibrosis. Individuals with these advanced stages of fibrosis are at a significantly higher risk of liver-related mortality.

The data being presented further characterize the potential role of three compounds they beget in development, their FXR agonist, GS-9674, their ASK1 inhibitor, selonsertib and their ACC inhibitor, GS-0976. They will besides present baseline data from STELLAR 3 and STELLAR 4, their two ongoing phase 3 trials evaluating selonsertib as monotherapy that narrate the potential role and sequence of non-invasive tests and their faculty to diagnose advanced fibrosis. Currently, liver biopsy, which is the standard routine to diagnose advanced fibrosis, poses challenges to timely and efficient diagnosis and treatment of patients with this disease.

Before they hotfoot on from NASH, I'd fancy to remind you that they anticipate data readouts from STELLAR 3 and STELLAR 4 in the first half of 2019. They are besides pleased to share that the phase 2b ATLAS study of various combination two-drug regimen in patients with NASH and advanced fibrosis has now closed screening. They are presenting data from a phase 2 trial evaluating their FXR agonist in primary sclerosing cholangitis. This is a rare serious disease that causes progressive inflammation and scarring of the bile ducts which can lead to cirrhosis and its complications, including liver failure. There are currently no efficacious treatment options available for these patients.

And finally at The Liver Meeting, they will besides share data from Gilead's ongoing programs directed at achieving functional cure of inveterate hepatitis B infected patients. GS-9688, an investigational oral selective toll-like receptor 8 agonist is the subject of several studies to live presented, including the first in human and phase 1b results evaluating the drug in patients with inveterate hepatitis B.

Turning to cell therapy, they continue to compose considerable scientific progress besides during the quarter. In August, they announced that European Commission granted Marketing Authorization for Yescarta as a treatment for adult patients with relapsed or refractory diffuse big B-cell lymphoma and primary mediastinal big B-cell lymphoma, after two or more lines of systemic therapy. They are making progress in reaching patients with other forms of B-cell malignancies also, with Yescarta and KTE-X19 (ph). Registrational phase 2 trials are ongoing with Yescarta in relapsed and refractory indolent NHL or non-Hodgkin's lymphoma and with KTE-X19 (ph) in relapsed and refractory mantle cell lymphoma and adult ALL.

We hope to broadcast additional data and trial updates from their cell therapy program at the American Society of Hematology Annual Meeting, ASH, which begins December 1 in San Diego. They will share more information with you next month when those meeting abstracts are published.

Separately in oncology, they discontinued the evolution of andecaliximab, an investigational anti-MMP9 antibody in gastric cancer, after a phase 3 study showed a want of overall survival profit to primary endpoint. These data are consistent with the results we're seeing with andecaliximab in other therapeutic programs.

We continued to pursue additional technologies and approaches that will allow us to remain the leader in cell therapy. Earlier this month, they announced another research collaboration and license agreement with HiFiBiO Therapeutics to develop technologies supporting the discovery of neoantigen-reactive T-cell receptors for the potential treatment of various cancers, particularly solid tumors.

Through this collaboration, they intend to reconcile HiFiBiO's proprietary single-cell technology platform to create a high throughput approach that will potentially allow for in-depth screening of TCR repertoires from patient samples to identify both shared antigen and neoantigen TCRs for exercise in adoptive T-cell therapy. Neoantigens arise from tumor specific mutations that are unique to each patient's cancer, offering the potential for more targeted anti-tumor activity. This zone of research has the potential to transform the way they might live able to treat many solid tumors.

I would fancy to besides note that these kinds of scientific collaborations are not limited to cell therapy. In September, they entered into a strategic collaboration with Precision BioSciences to develop therapies targeting the in vivo elimination of HBV or hepatitis B virus with Precision's proprietary genome editing platform, ARCUS. They are committed to developing therapies to achieve a functional cure for patients with inveterate hepatitis B virus. They are excited about the potential of genome editing and Precision's ARCUS technology, which has already demonstrated promising in vitro activity.

We beget achieved a considerable deal across their R&D organization this quarter, and I'm confident they will continue to compose significant progress throughout the leisure of the year. I'm excited about the strength and diversity of their pipeline, as described today, the breakthrough work they are doing in cell therapy and the cutting-edge research they are doing to forward curative therapies, both for hepatitis B and HIV infected patients. I want to pick the opening to thank their R&D organization and totality of their employees for their incredible focus, hard work and execution.

So, thank you all. And now, I'd fancy to turn the muster over to John Milligan.

John Milligan -- President and Chief Executive Officer

Thank you, John. righteous afternoon, everyone. As they approach the halt of the year and head into 2019, they beget many reasons to feel confident about the strength of their commerce and the future of their company. Their long-term leadership in HIV continues. We're having a terrific launch of Biktarvy, which is exceeding their high expectations and is on track to become the most successful ever in HIV through the first year of sales. They besides beget compelling evidence correlating the exercise of Truvada for PrEP with declines in fresh infections in the United States, further demonstrating its significance as an efficacious public health intervention in the ongoing efforts to meaningfully lessen fresh infections.

While considerable progress has been made in both treatment and prevention over the final two decades, they believe there is still plenty of scope for innovation in HIV. They are pursuing research that could abet patients who beget speed out of options as a result of viral resistance or who may exigency less frequent dosing than afforded by a daily pill. And finally, they hope that their research may one day abet lead to a cure, completely removing the virus from patients once and for totality as they did for patients in HCV.

In HCV, they continue to innovate to expand access and support efforts toward elimination of the virus from the human population. In January, just over five years after the launch of Sovaldi, their newly formed subsidiary, Asegua, they will launch authorized generic versions of Epclusa and Harvoni in the United States. They believe this will abet reduce out of pocket expenses for many patients, enlarge price transparency and open up access to their HCV medicines for patients covered by Medicaid without disruption to the broader healthcare environment.

One year after the acquisition of Kite, Gilead is the leader in cell therapy and Yescarta access for people with the relapsed refractory DLBCL is now established in over 60 centers in the United States. Yescarta has shown an unprecedented duration of response in clinical studies, and they beget now treated nearly 700 patients across clinical trials and commercial use. The high percentage of patients showing a durable response following the single cellular fusion gives us a glimpse into the potential of cellular therapy to radically change the cancer treatment paradigm in the future, perhaps across many different tumor types. Over the final year, they beget established six technology product-based partnerships that will allow us to build on their leadership position in cell therapy and transform the treatment of cancer.

We beget a maturing pipeline and are now nascence to descry the first of many phase 3 readouts of filgotinib in inflammation. They are pleased that the efficacy and safety of filgotinib looks to live consistent with the datasets from the long-term phase 2 studies and believe filgotinib shows considerable pledge to abet patients in a number of different indications.

Finally, Gilead has dedicated gargantuan resources to understanding the biology and pathology of NASH. These efforts are paying off with three compounds in the clinic, including an extensive array of phase 2 combination studies. Next year, we'll descry the first phase 3 readouts of selonsertib as the STELLAR 3 and STELLAR 4 clinical studies are completed and unblinded. They gape forward to seeing the data, and their teams are hard at work preparing for the launch of selonsertib into this brand fresh disease area.

The work of Gilead goes on, even as I prepare to depart at the halt of the year. To everyone who has supported us in their mission over the years, thank you. I beget every self-confidence in my team's faculty to continue the work of bringing forward therapeutics that dramatically help lives. To Gilead's more than 11,000 employees, I besides want to thank you. It's been a privilege to live a leader for the final three years and to work with you for the final 29. It's been deeply gratifying to live fragment of a company that has brought life-saving treatments to 10 million people around the globe. I gape forward to watching the continued evolution of Gilead and the extraordinary things I know you will accomplish.

So, let's open it up for questions. Operator?

Questions and Answers:

Operator

Thank you. Ladies and gentlemen, today's question-and-answer session will live conducted electronically. (Operator Instructions) Their first question comes from Geoff Meacham with Barclays.

Geoff Meacham -- Barclays -- Analyst

Good afternoon, everyone. Thanks for the question. John, really they will miss your leadership and I want to add congrats besides to Laura on the fresh role. Just had a few on HIV. If you guys could give any more perspective on switches to Biktarvy, beyond dolutegravir. Are you seeing switches from generic regimens as well? And then on PrEP, I know you don't beget data yet, but what's the initial thought on positioning for Descovy over Truvada? And how finish you believe that plays out following the Truvada LOE? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

So, in terms of switches, Geoff, as I mentioned, they are seeing that the majority of the Biktarvy prescriptions are coming from switches, about 85% to live exact. And approximately a quarter of those are coming from dolutegravir containing regimens. There is besides about 25% coming from Genvoya as well, so (inaudible) balance. And then the latter half of your question, Geoff, can you repeat it?

Geoff Meacham -- Barclays -- Analyst

Descovy for PrEP.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Oh, Descovy for PrEP. John.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Yes. John here. Look, the question of Descovy versus Truvada for PrEP, people who are healthy, which is the people who are taking PrEP are, deserve and want the easiest and safest and best tolerated medication. So that is Descovy. So I believe that's a pretty straightforward respond to that question.

Operator

Thank you. Their next question comes from Brian Abrahams with RBC Capital Markets.

Brian Abrahams -- RBC Capital Markets -- Analyst

Hey, guys. Thanks very much for taking my question and congrats on the quarter. On filgotinib, with the phase 3 starting to rollout, I was wondering if you could provide your latest views on what you descry as the key differentiating features or indications? And maybe walk us through your latest plans in how you're thinking about pile out a commercial infrastructure in inflammation, particularly with some of the fresh leadership now in place? Thanks.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

So I'll start first. So, after attending ACR this week and being at the meeting, it's lucid that the efficacy that they are generating in multiple inflammatory diseases with filgotinib is as righteous or if not better than any other drug in the class, and equivalent to the biologics. And that holds lawful for FINCH 2 where they just saw the most difficult patients to treat, the biologic non-responders, inadequate responder patients where their ACR20 rates in people who had received three or more biologics previously was over 70%, just over 70%. So, I believe efficacy wise, they are as righteous if not better than anything else out there in the class.

Safety wise, they continue to descry the differentiation based upon the lab parameters -- anemia, the want of anemia, the want of result on platelets and when they gape at other clinical events such as thromboembolic events and other events, they are not seeing anything difference. They beget to descry that safety profit and odds hold up in the subsequent phase 3 clinical programs. The same as the other diseases, they are seeing those benefits as well. So, I'll hand it over to the other folks about the commercial build out, et cetera.

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

So, hi. This is Laura. I would negate on the commercial structure, they will build a commercial field team that is competitive across totality indications. And as you know, they are aware of the investment that's necessary to compete in this market and they will live reaching consumers in innovative ways to compose sure that they are aware of the profile that we'll live able to bring to the market to abet them.

Operator

Thank you. Their next question comes from Michael Yee with Jefferies.

Michael Yee -- Jefferies -- Analyst

Thanks. appreciate the question. And, John, I'm sure they totality heard the emotion in the voice, so they appreciate totality the work you've done and for totality the years. I guess my question is, it feels fancy the Street has two uncertainties; one is a bit on hep C and one is, I guess, to an extent, an update on the fresh leadership that will give people self-confidence going forward. Perhaps you can give a comment as to your self-confidence around the US hep C market stabilizing and whether there's any changes and how that authorized generic helps that, if at all? And then if you can compose a comment on where they stand on the leadership change? I believe that would abet people as well. Thanks.

John Milligan -- President and Chief Executive Officer

Yeah. Hi, Michael. So let's just -- talking about the US hep C market, what they beget seen through the course of the year is a fairly stable pricing environment but, of course, declining patient numbers, particularly in the commercial markets and to some extent the Medicare markets. So, they believe the authorized generic will actually boost us for the future because number one, it provides more transparency, which is righteous for everybody. It will pick away some of the twinge of the co-pays that are provided, especially into the Medicare population. But most importantly, it'll open up access for us into the Medicaid population, which is the largest growing segment of patients for the future. So they believe that totality this will enhance their faculty to compete for the future and really abet stabilize this market going into 2019 and beyond. So all-in-all, a very positive thing for us.

With esteem to the CEO search, I really can't negate anything specific, other than to negate there are many candidates who are very interested. The process is pitiful along quickly, and they certainly hope to beget somebody announced before the halt of the year.

Operator

Thank you. Their next question comes from Matthew Harrison with Morgan Stanley.

Matthew Harrison -- Morgan Stanley -- Analyst

Great. righteous afternoon. Thanks for taking the question. I had one related to some of the Kite programs. I noticed in the slides you indicated that you'd live making a determination on your BCMA CAR, whether to hotfoot into a registrational study in the fourth quarter. I'm just wondering what data you're waiting for to compose that determination and how you're going to communicate that decision? Thanks.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Sure. Hi, Michael.

John Milligan -- President and Chief Executive Officer

Matt, this is Matt.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Matt, sorry. Look, yes, it's unchanged. They are waiting for data from the phase 1b trial, which is looking at escalating dose cohorts, the safety and efficacy in myeloma patients of KITE-585. And then we'll broadcast the start of a phase 2 trial if the data supports that. So, no change to what we've said previously and we're in the process of that perquisite now.

Operator

Thank you. Their next question comes from Geoffrey Porges with Leerink.

Geoffrey Porges -- Leerink -- Analyst

Thank you very much. And, John, I just want to congratulate you on totality the accomplishments over those 29 years. I'm sure if you beget any free time, John McHutchison might lend you his AO for a bit of travel. I just wanted to quiz John McHutchison a Little bit about a pair of pipeline contingencies. First, you mentioned the MANTA study. And obviously, you'll beget the three FINCH studies by the -- in the first half of the year. Is it feasible that, that filing could live delayed until 2020? Or is there any way you could start filing with the clinical data and then append the MANTA data to the filing?

And then secondly, will you beget a haphazard to gape at the interim data from the combination NASH study and then potentially contemplate pivotal trials to some combination earlier than the 48-week data? Thanks.

John Milligan -- President and Chief Executive Officer

Yeah.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Thank you, Geoff. Starting with MANTA, considerable question. They beget spent an inordinate amount of effort trying to enhance the enrollment in the MANTA study. It's too early to gauge the effectiveness of those modifications to inclusion criteria, et cetera. I believe we'll provide an update in the future when they can beget more clarity about the timeline.

I will negate they are having discussions internally and with regulators about different options, as one of which you outlined as well. And as you know, in various parts of the world you can file and you can file updates at various different times of the review process. So each region and each zone is different. So we're having totality of these discussions and spending a lot of my effort and a lot of the team's effort on that as well.

In terms of the ATLAS, your second question, in terms of the ATLAS phase 2b 350 patient NASH combination study. Yes, they will pick a gape at week 24. And week 24 gape we're allowed to finish an statistical analysis plan. It's not biopsy-driven, it's driven by MRA FibroScan, lab tests, MRI-PDFF. So they will live able to beget a look. And if there's lucid separation without biopsy, they can determine to hotfoot early to phase 3 if we're convinced that's the perquisite thing to do.

Operator

Thank you. Their next question comes from Robyn Karnauskas with Citi.

Greg Harrison -- Citi -- Analyst

Hi. This is Greg Harrison on for Robyn. Thank you for taking the question. So in hep B, given the Arrowhead data we've seen recently, finish you believe that you exigency an S antigen component in your combos? Or are you satisfied with what you beget internally?

John McHutchison -- Chief Scientific Officer and Head of Research and Development

I don't believe we're ever satisfied with what they beget internally. And they beget a number of internal programs that are looking at interfering in S in various different ways, either by direct mechanisms or through induction of HBV-specific immunity. And they are besides always looking for what they believe is additionally valuable to what they are doing internally, externally as well. They are watching the siRNA field closely besides and aware of what Arrowhead's done. They gape forward to seeing the data presented in complete at AASLD.

Operator

Thank you. Their next question comes from Umer Raffat with Evercore.

Umer Raffat -- Evercore -- Analyst

Hi, guys. Thanks for taking my question. And John, wanted to extend their congratulations on totality of your's and Gilead's success over the years. My question was perhaps two-fold. One, going forward for the fresh CEO, is there specific expectations that the board has set? May that live on specific M&A targets, dollar size, number of transactions? Just wanted to derive a flavor for the direction for the company and board's expectations.

And then secondly on CAR T, they heard your commentary on the variability in adoption. And my question is, Street has a 50% growth over the next four quarters for Yescarta franchise. And given how valuable a launch it is, my question is, finish you remain confident in that type of growth trajectory?

John Milligan -- President and Chief Executive Officer

So first let me start with the specific criteria for a fresh CEO. That's not typically how things are done. There are conversations and looking at different strategies that a fresh CEO could bring to Gilead. But, no, there are no specific targets or directions that were given by the board.

So secondly, and question about CAR T is a righteous one. So if you believe about CAR T and you believe about the shift in paradigm that has to occur in a treatment headquarters to adopt it, it requires lots of collaboration across multiple departments. It requires novel ways of thinking about billing and treating patients. And it takes time for these centers to arrive up to speed. The centers that were early adopters of CAR T and are still the biggest users of Yescarta, beget a lot of suffer and beget kindhearted of worked out the treatment, and frankly, commerce paradigm of cellular therapy. And that's where we're seeing the majority of their success today.

The middle adopters and now the late adopters are the groups that are really trying to motif out how to compose this work within their institution and how to compose this commerce model work for their hospital in particular and that can pick some time. So what they would hope is that, as these centers start to treat, as they work out how to build the commercial plans, as they motif out how to derive reimbursement through -- for Medicare patients, this will grow over time. And, of course, we'll descry some centers that beget greater adoption and some that beget less.

So, I finish believe that with the data that are emerging on CAR T with the growing cadaver of evidence that a high percentage of patients can beget very durable responses, this is something that will grow to become of significance in totality 60 centers that we're in. But it is going to pick some time to derive the growth rate that they need. I won't comment to any specifics. But I'm very confident that as they derive better at this, as the medical rehearse gets better, as they derive better at managing some of the side effects around this, and then importantly in the future, as they derive a DRG code, this will grow into a very valuable commerce for Gilead. And it will live very, very valuable for patients who beget speed out of options.

Operator

Thank you. Their next question comes from Alethia Young with Cantor Fitzgerald.

Alethia Young -- Cantor Fitzgerald -- Analyst

Hey, guys. Thanks for taking my question. Congrats on Biktarvy. And John, you certainly will live missed and they truly enjoyed seeing him serving the leadership over such a long tenure. I guess I beget a question on HIV and generics in Europe. You said obviously you've seen some impact and there actually beget been some company -- countries where you haven't thought -- you thought you would descry impact and didn't. So, can you talk a Little bit more about those unavoidable dynamics there? Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Sure, Alethia. Congrats on your fresh role as well. Yeah, they continue to descry adoption of generics across Europe. I believe what we're seeing is differentiation across the different countries relative to timing and the uptake of generics. They talked about the uptake of Descovy, that continues to travel really well and they believe that's thwarting some of that uptake. Particularly in Italy and UK, we're just not seeing the uptake of generics as quickly as they thought they would pick hold. And that's something that they factored into their guidance to the tune of $100 million. I believe even in 2019, we'll continue to descry uptakes of generics, but with the launch of Biktarvy, et cetera, they believe we'll live well competitively positioned and believe totality the benefits of Descovy will abet us continue to grow share in their ex-US markets.

Operator

Thank you. Their next question comes from Phil Nadeau with Cowen.

Phil Nadeau -- Cowen -- Analyst

Good afternoon. John, let me add my congratulations on totality that you've accomplished and best of luck on your next act. My question is on the guidance. It looks fancy that even at the top halt of the guidance, you're projecting a sequentially down quarter in Q4. inquisitive to derive a Little bit more information on what elements finish you believe are going to beget a quarter-over-quarter decline? Is that HCV? Is that EU HIV? Any information you could give us would live appreciated. Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Sure, Phil. I won't travel -- again, they kindhearted of gave a basis of their guidance. First, let me just negate we're really very satisfied with how the year has gone and the faculty to raise guidance at this point. Everything that we've talked about from HIV being a growth franchise to HCV stabilizing, Yescarta continuing to beget a nice tedious and steady build. I mean, I believe overall, totality of their franchises are performing very well. There's a pair of dynamics. You mentioned a few. One HCV, as they said, while stabilizing they finish continue to descry declines in patient starts. That's the primary driver.

Recall they talked final quarter about a price freeze for the next six months, which if you believe about a typical Q4, they sometimes descry inventory build in Q4 in forward of that price increase. And I'm not saying they won't beget any inventory build, some of that is just fragment of supply chain, but they finish anticipate that there may live a Little less. And as I mentioned, the other driver of their raise in guidance was Letairis and the LOE, which is here. They haven't seen any impacts. That could happen, right. So they are providing a purview of guidance, but we're very confident with their faculty to meet the guidance and hope to overachieve it.

Operator

Thank you. Their next question comes from Cory Kasimov with JPMorgan.

Cory Kasimov -- JPMorgan -- Analyst

Hey. righteous afternoon, guys. Thanks for taking my question. I guess first to John, congrats again on a really considerable run. So I guess my question is on Biktarvy on the heels of another really impressive quarter for the product. I'm just inquisitive if there was any meaningful contribution from inventory build or any other type of one-time item? Or is this really totality just demand-driven? Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Hi, Cory. considerable question. Now their sequential growth was totality demand driven. They didn't descry really any change in inventory and as you're probably recalling final quarter, I talked about the fact that they were at a 50-50 payer mix between commercial and government and there was the haphazard that that would beget shifted back to what we've traditionally seen, 45% commercial, 55% government. But they didn't descry that. And these payer mix percentages finish fluctuate quarter-to-quarter really depending on the buying patterns from government payers, such as ADAP. So, overall, a strong demand-driven quarter for Biktarvy, again this -- and HIV overall, no impact from inventory or payer mix.

Operator

Thank you. Their next question comes from Terence Flynn with Goldman Sachs.

Terence Flynn -- Goldman Sachs -- Analyst

Hi. Thanks for taking the question. Maybe just a pair of follow-ups on Biktarvy and the TAF portfolio. First, can you just comment on European pricing dynamics for Biktarvy, now that you're a Little bit further in and maybe abet us believe about that heading into 2019? And then can you guys disclose total TAF volume in Europe perquisite now? I know you give us that for the US, but just wondering where it stands in Europe? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Yeah, So it's hard to talk about volume because of generics. They finish talk about TAF or Descovy based as a percentage of revenue, and it's about 70% of revenues in US. Pricing really hasn't been a barrier, maintain in mind, they priced -- their Descovy regimens are pretty much priced similar to Stribild, et cetera (inaudible) Biktarvy. So it's really been righteous overall uptake. I believe we'll always descry competitiveness in European pricing, but that's something that we're used to. So, it really fundamentally has been just the desire for more and more patients who want to hotfoot to Descovy-based regimens that has been driving their performance offset by the adoption of generic.

Operator

Thank you. Their next question comes from Ying Huang with Bank of America Merrill Lynch.

Ying Huang -- Bank of America Merrill Lynch -- Analyst

Hi. Thanks for taking my questions, and congrats to John as well. So, first one on Yescarta, I think, Robin, you mentioned that now you finish beget this fresh technology add-on payment. I was wondering how much that helps the adoption for Yescarta under that? And how much is this pecuniary loss is actually stopping the centers from adopting Yescarta?

And then secondly, they noticed that you beget exclusive status with Express Scripts for 2019 and Mavyret from AbbVie was excluded. Does that carry weight there is additional pricing concessional rebate provided by Gilead? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

So, let me start with the prior question. Yeah, I believe as always is their case, they are always working and negotiating with payers. I won't -- can't talk specifically to the details of a contract, but they are blissful that they beget reached the formulary ranking with Express Scripts, and it's something that we've talked totality about that, they continue to live out there competing in this marketplace. There's besides Mavyret, and they continue to finish well.

I believe to your other question relative to Yescarta. Yeah, the NTAP, as I said, it's a start. As they understand it, it's about 50% of reimbursement. To sit and command you what every hospital makes or doesn't make, that's very hard for me to comment on. That's very contingent on their relationship with the payers, et cetera. So, I can't give you more details on that. I finish believe the NTAP is a start, and they are working very, very diligently and hard to continue to display the value of this treatment, and hopefully eventually descry DRG specifics for CAR T therapy.

Operator

Thank you. And their final question comes from Steven Seedhouse with Raymond James.

Steven Seedhouse -- Raymond James -- Analyst

Hi. Thank you for taking the question. Just on NASH, understanding the hope is obviously that both STELLAR 3 and STELLAR 4 succeed. I'm inquisitive if there is a viable filing strategy or path forward for either monotherapy or combination therapies for selonsertib in basically refined fibrosis subset of NASH patients if one of those two phase 3 trial hits the primary endpoint or beget you designed the clinical program such that both phase 3 trials exigency to work to hotfoot selonsertib forward? Thank you.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

So, it's a righteous question regarding the STELLAR programs, and I believe the respond to your question lies in the STELLAR programs where their discussions with regulators were around both trials independently, but I believe everybody understands that a third of patients with F3 really beget F4, and a third of patients with F4 beget F3. So, if for example there was a situation where one trial was positive and one trial was negative, they would live able to gape at different subgroups of patients, but that would live a completely unscripted discussion that would just depend on what the data looked fancy at that time.

Operator

Thank you for participating in today's question-and-answer session. I would now fancy to turn the muster back over to Sung Lee for any closing remarks.

Sung Lee -- Vice President of Investor Relations

Thank you, Cherie and thank you totality for joining us today. They appreciate your continued interest in Gilead, and the team here looks forward to providing you with updates on their future progress.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may totality disconnect, and beget a wonderful day.

Duration: 57 minutes

Call participants:

Sung Lee -- Vice President of Investor Relations

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

John McHutchison -- Chief Scientific Officer and Head of Research and Development

John Milligan -- President and Chief Executive Officer

Geoff Meacham -- Barclays -- Analyst

Brian Abrahams -- RBC Capital Markets -- Analyst

Michael Yee -- Jefferies -- Analyst

Matthew Harrison -- Morgan Stanley -- Analyst

Geoffrey Porges -- Leerink -- Analyst

Greg Harrison -- Citi -- Analyst

Umer Raffat -- Evercore -- Analyst

Alethia Young -- Cantor Fitzgerald -- Analyst

Phil Nadeau -- Cowen -- Analyst

Cory Kasimov -- JPMorgan -- Analyst

Terence Flynn -- Goldman Sachs -- Analyst

Ying Huang -- Bank of America Merrill Lynch -- Analyst

Steven Seedhouse -- Raymond James -- Analyst

More GILD analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference muster produced for The Motley Fool. While they strive for their absurd Best, there may live errors, omissions, or inaccuracies in this transcript. As with totality their articles, The Motley Fool does not assume any responsibility for your exercise of this content, and they strongly embolden you to finish your own research, including listening to the muster yourself and reading the company's SEC filings. tickle descry their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

More From The Motley Fool

Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: long November 2018 $78 calls on Gilead Sciences. The Motley Fool has a disclosure policy.


Express, Inc. Announces Earnings Release Date, Conference muster and Webcast for Fourth Quarter and Fiscal 2016 Results | killexams.com existent questions and Pass4sure dumps

COLUMBUS, Ohio--(BUSINESS WIRE)--Express, Inc. (NYSE: EXPR), a specialty retail apparel company, today announced that it will conduct a conference muster to argue fourth quarter and fiscal year 2016 results on Wednesday, March 8, 2017, at 9:00 a.m. ET. Earlier that morning, the Company will issue a press release detailing those results. The conference muster will live hosted by David Kornberg, president and chief executive officer, Matthew Moellering, executive vice president and chief operating officer, and Perry Pericleous, senior vice president and chief pecuniary officer.

Investors and analysts interested in participating in the muster are invited to dial (877) 705-6003 approximately ten minutes prior to the start of the call. The conference muster will besides live webcast live at: http://www.express.com/investor and remain available for 90 days. A telephone replay of this muster will live available at 12:00 p.m. ET on March 8, 2017, until 11:59 p.m. ET on March 15, 2017, and can live accessed by dialing (844) 512-2921 and entering the replay pin number 13654883.

In addition, an investor presentation of fourth quarter and fiscal year 2016 results will live available at: http://www.express.com/investor at approximately 7:00 a.m. ET on Wednesday, March 8, 2017.

About Express, Inc.:

Express is a specialty apparel and accessories retailer of women's and men's merchandise, targeting the 20 to 30- year-old customer. Express has more than 35 years of suffer offering a distinct combination of vogue and attribute for multiple lifestyle occasions at an attractive value addressing vogue needs across work, casual, jeanswear, and going-out occasions. The Company currently operates more than 650 retail and factory outlet stores, located primarily in high-traffic shopping malls, lifestyle centers, and street locations across the United States, Canada, and Puerto Rico. Express merchandise is besides available at franchise locations in Latin America. Express besides markets and sells its products through its e-commerce website, www.express.com, as well as on its mobile app.



Direct Download of over 5500 Certification Exams

3COM [8 Certification Exam(s) ]
AccessData [1 Certification Exam(s) ]
ACFE [1 Certification Exam(s) ]
ACI [3 Certification Exam(s) ]
Acme-Packet [1 Certification Exam(s) ]
ACSM [4 Certification Exam(s) ]
ACT [1 Certification Exam(s) ]
Admission-Tests [13 Certification Exam(s) ]
ADOBE [93 Certification Exam(s) ]
AFP [1 Certification Exam(s) ]
AICPA [2 Certification Exam(s) ]
AIIM [1 Certification Exam(s) ]
Alcatel-Lucent [13 Certification Exam(s) ]
Alfresco [1 Certification Exam(s) ]
Altiris [3 Certification Exam(s) ]
Amazon [2 Certification Exam(s) ]
American-College [2 Certification Exam(s) ]
Android [4 Certification Exam(s) ]
APA [1 Certification Exam(s) ]
APC [2 Certification Exam(s) ]
APICS [2 Certification Exam(s) ]
Apple [69 Certification Exam(s) ]
AppSense [1 Certification Exam(s) ]
APTUSC [1 Certification Exam(s) ]
Arizona-Education [1 Certification Exam(s) ]
ARM [1 Certification Exam(s) ]
Aruba [6 Certification Exam(s) ]
ASIS [2 Certification Exam(s) ]
ASQ [3 Certification Exam(s) ]
ASTQB [8 Certification Exam(s) ]
Autodesk [2 Certification Exam(s) ]
Avaya [96 Certification Exam(s) ]
AXELOS [1 Certification Exam(s) ]
Axis [1 Certification Exam(s) ]
Banking [1 Certification Exam(s) ]
BEA [5 Certification Exam(s) ]
BICSI [2 Certification Exam(s) ]
BlackBerry [17 Certification Exam(s) ]
BlueCoat [2 Certification Exam(s) ]
Brocade [4 Certification Exam(s) ]
Business-Objects [11 Certification Exam(s) ]
Business-Tests [4 Certification Exam(s) ]
CA-Technologies [21 Certification Exam(s) ]
Certification-Board [10 Certification Exam(s) ]
Certiport [3 Certification Exam(s) ]
CheckPoint [41 Certification Exam(s) ]
CIDQ [1 Certification Exam(s) ]
CIPS [4 Certification Exam(s) ]
Cisco [318 Certification Exam(s) ]
Citrix [47 Certification Exam(s) ]
CIW [18 Certification Exam(s) ]
Cloudera [10 Certification Exam(s) ]
Cognos [19 Certification Exam(s) ]
College-Board [2 Certification Exam(s) ]
CompTIA [76 Certification Exam(s) ]
ComputerAssociates [6 Certification Exam(s) ]
Consultant [2 Certification Exam(s) ]
Counselor [4 Certification Exam(s) ]
CPP-Institue [2 Certification Exam(s) ]
CPP-Institute [1 Certification Exam(s) ]
CSP [1 Certification Exam(s) ]
CWNA [1 Certification Exam(s) ]
CWNP [13 Certification Exam(s) ]
Dassault [2 Certification Exam(s) ]
DELL [9 Certification Exam(s) ]
DMI [1 Certification Exam(s) ]
DRI [1 Certification Exam(s) ]
ECCouncil [21 Certification Exam(s) ]
ECDL [1 Certification Exam(s) ]
EMC [129 Certification Exam(s) ]
Enterasys [13 Certification Exam(s) ]
Ericsson [5 Certification Exam(s) ]
ESPA [1 Certification Exam(s) ]
Esri [2 Certification Exam(s) ]
ExamExpress [15 Certification Exam(s) ]
Exin [40 Certification Exam(s) ]
ExtremeNetworks [3 Certification Exam(s) ]
F5-Networks [20 Certification Exam(s) ]
FCTC [2 Certification Exam(s) ]
Filemaker [9 Certification Exam(s) ]
Financial [36 Certification Exam(s) ]
Food [4 Certification Exam(s) ]
Fortinet [12 Certification Exam(s) ]
Foundry [6 Certification Exam(s) ]
FSMTB [1 Certification Exam(s) ]
Fujitsu [2 Certification Exam(s) ]
GAQM [9 Certification Exam(s) ]
Genesys [4 Certification Exam(s) ]
GIAC [15 Certification Exam(s) ]
Google [4 Certification Exam(s) ]
GuidanceSoftware [2 Certification Exam(s) ]
H3C [1 Certification Exam(s) ]
HDI [9 Certification Exam(s) ]
Healthcare [3 Certification Exam(s) ]
HIPAA [2 Certification Exam(s) ]
Hitachi [30 Certification Exam(s) ]
Hortonworks [4 Certification Exam(s) ]
Hospitality [2 Certification Exam(s) ]
HP [746 Certification Exam(s) ]
HR [4 Certification Exam(s) ]
HRCI [1 Certification Exam(s) ]
Huawei [21 Certification Exam(s) ]
Hyperion [10 Certification Exam(s) ]
IAAP [1 Certification Exam(s) ]
IAHCSMM [1 Certification Exam(s) ]
IBM [1530 Certification Exam(s) ]
IBQH [1 Certification Exam(s) ]
ICAI [1 Certification Exam(s) ]
ICDL [6 Certification Exam(s) ]
IEEE [1 Certification Exam(s) ]
IELTS [1 Certification Exam(s) ]
IFPUG [1 Certification Exam(s) ]
IIA [3 Certification Exam(s) ]
IIBA [2 Certification Exam(s) ]
IISFA [1 Certification Exam(s) ]
Intel [2 Certification Exam(s) ]
IQN [1 Certification Exam(s) ]
IRS [1 Certification Exam(s) ]
ISA [1 Certification Exam(s) ]
ISACA [4 Certification Exam(s) ]
ISC2 [6 Certification Exam(s) ]
ISEB [24 Certification Exam(s) ]
Isilon [4 Certification Exam(s) ]
ISM [6 Certification Exam(s) ]
iSQI [7 Certification Exam(s) ]
ITEC [1 Certification Exam(s) ]
Juniper [63 Certification Exam(s) ]
LEED [1 Certification Exam(s) ]
Legato [5 Certification Exam(s) ]
Liferay [1 Certification Exam(s) ]
Logical-Operations [1 Certification Exam(s) ]
Lotus [66 Certification Exam(s) ]
LPI [24 Certification Exam(s) ]
LSI [3 Certification Exam(s) ]
Magento [3 Certification Exam(s) ]
Maintenance [2 Certification Exam(s) ]
McAfee [8 Certification Exam(s) ]
McData [3 Certification Exam(s) ]
Medical [69 Certification Exam(s) ]
Microsoft [368 Certification Exam(s) ]
Mile2 [2 Certification Exam(s) ]
Military [1 Certification Exam(s) ]
Misc [1 Certification Exam(s) ]
Motorola [7 Certification Exam(s) ]
mySQL [4 Certification Exam(s) ]
NBSTSA [1 Certification Exam(s) ]
NCEES [2 Certification Exam(s) ]
NCIDQ [1 Certification Exam(s) ]
NCLEX [2 Certification Exam(s) ]
Network-General [12 Certification Exam(s) ]
NetworkAppliance [36 Certification Exam(s) ]
NI [1 Certification Exam(s) ]
NIELIT [1 Certification Exam(s) ]
Nokia [6 Certification Exam(s) ]
Nortel [130 Certification Exam(s) ]
Novell [37 Certification Exam(s) ]
OMG [10 Certification Exam(s) ]
Oracle [269 Certification Exam(s) ]
P&C [2 Certification Exam(s) ]
Palo-Alto [4 Certification Exam(s) ]
PARCC [1 Certification Exam(s) ]
PayPal [1 Certification Exam(s) ]
Pegasystems [11 Certification Exam(s) ]
PEOPLECERT [4 Certification Exam(s) ]
PMI [15 Certification Exam(s) ]
Polycom [2 Certification Exam(s) ]
PostgreSQL-CE [1 Certification Exam(s) ]
Prince2 [6 Certification Exam(s) ]
PRMIA [1 Certification Exam(s) ]
PsychCorp [1 Certification Exam(s) ]
PTCB [2 Certification Exam(s) ]
QAI [1 Certification Exam(s) ]
QlikView [1 Certification Exam(s) ]
Quality-Assurance [7 Certification Exam(s) ]
RACC [1 Certification Exam(s) ]
Real-Estate [1 Certification Exam(s) ]
RedHat [8 Certification Exam(s) ]
RES [5 Certification Exam(s) ]
Riverbed [8 Certification Exam(s) ]
RSA [15 Certification Exam(s) ]
Sair [8 Certification Exam(s) ]
Salesforce [5 Certification Exam(s) ]
SANS [1 Certification Exam(s) ]
SAP [98 Certification Exam(s) ]
SASInstitute [15 Certification Exam(s) ]
SAT [1 Certification Exam(s) ]
SCO [10 Certification Exam(s) ]
SCP [6 Certification Exam(s) ]
SDI [3 Certification Exam(s) ]
See-Beyond [1 Certification Exam(s) ]
Siemens [1 Certification Exam(s) ]
Snia [7 Certification Exam(s) ]
SOA [15 Certification Exam(s) ]
Social-Work-Board [4 Certification Exam(s) ]
SpringSource [1 Certification Exam(s) ]
SUN [63 Certification Exam(s) ]
SUSE [1 Certification Exam(s) ]
Sybase [17 Certification Exam(s) ]
Symantec [134 Certification Exam(s) ]
Teacher-Certification [4 Certification Exam(s) ]
The-Open-Group [8 Certification Exam(s) ]
TIA [3 Certification Exam(s) ]
Tibco [18 Certification Exam(s) ]
Trainers [3 Certification Exam(s) ]
Trend [1 Certification Exam(s) ]
TruSecure [1 Certification Exam(s) ]
USMLE [1 Certification Exam(s) ]
VCE [6 Certification Exam(s) ]
Veeam [2 Certification Exam(s) ]
Veritas [33 Certification Exam(s) ]
Vmware [58 Certification Exam(s) ]
Wonderlic [2 Certification Exam(s) ]
Worldatwork [2 Certification Exam(s) ]
XML-Master [3 Certification Exam(s) ]
Zend [6 Certification Exam(s) ]





References :


Dropmark : http://killexams.dropmark.com/367904/11794404
Wordpress : http://wp.me/p7SJ6L-1Hp
Dropmark-Text : http://killexams.dropmark.com/367904/12563882
Blogspot : http://killexamsbraindump.blogspot.com/2017/12/httpkillexamsbraindumpblogspotcom201712_15.html
RSS Feed : http://feeds.feedburner.com/EnsureYourSuccessWithThis920-130QuestionBank
Box.net : https://app.box.com/s/brtyf12yc39qzuc6xrpjhwlyzt5cgdss






Back to Main Page





Killexams exams | Killexams certification | Pass4Sure questions and answers | Pass4sure | pass-guaratee | best test preparation | best training guides | examcollection | killexams | killexams review | killexams legit | kill example | kill example journalism | kill exams reviews | kill exam ripoff report | review | review quizlet | review login | review archives | review sheet | legitimate | legit | legitimacy | legitimation | legit check | legitimate program | legitimize | legitimate business | legitimate definition | legit site | legit online banking | legit website | legitimacy definition | pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | certification material provider | pass4sure login | pass4sure exams | pass4sure reviews | pass4sure aws | pass4sure security | pass4sure cisco | pass4sure coupon | pass4sure dumps | pass4sure cissp | pass4sure braindumps | pass4sure test | pass4sure torrent | pass4sure download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://www.radionaves.com/